Zynex CEO Thomas Sandgaard discusses leadership transition - ICYMI

Core Insights - Zynex Inc's CEO Thomas Sandgaard announced his decision to step down after nearly 30 years, citing the need for new leadership to continue the company's growth [1][2] - The company has successfully helped over a million patients manage pain and generated hundreds of millions in revenue [2][4] Leadership Transition - Steven Dyson, a seasoned healthcare executive with 25 years of experience, has been identified as the successor and will officially take over in August [3][4] - The decision to transition leadership was influenced by a failed attempt to take Zynex private, which highlighted the need for a fresh perspective to enhance market capitalization and valuation [3][5] Company History and Achievements - Zynex was founded with no initial funding, and Sandgaard faced numerous challenges, including public listings and operational expansion [1][2] - The company achieved a significant milestone by uplisting to the OTC market eight years ago, which was crucial for financing and growth [2][3] - Sandgaard expressed pride in building a strong team and overcoming numerous challenges throughout the company's history [4][5]